Nestle

Last updated January 31, 2026

125

Innovation Areas

3,230

Inventors

Collaborations

Metabolomic biomarker concentration profiling: NestleRecent Research Landscape

Subjective diagnosis of mood disorders leads to misclassification and ineffective treatment. These innovations utilize specific chemical species like trigonelline and N-acetyl-L-tryptophan to provide objective biochemical measurement for clinical validation.

What technical problems is Nestle addressing in Metabolomic biomarker concentration profiling?

Subjective mood assessment inaccuracy

(4)evidences

Clinical reliance on self-reported symptoms leads to diagnostic inconsistency and measurement bias. Quantifiable chemical indicators provide an objective baseline for psychiatric evaluation.

Subjective mood disorder diagnosis

(4)evidences

Current psychiatric assessments rely on qualitative self-reporting and clinical observation rather than objective physiological metrics. Establishing quantifiable chemical indicators eliminates diagnostic variability and bias.